Perspective Therapeutics (CATX) Stock Price, News & Analysis

Company Overview

Perspective Therapeutics, Inc. (NYSE:CATX) is a clinical‐stage biotechnology company dedicated to developing ultra‐small targeted radiopharmaceuticals for the treatment and diagnosis of cancer. Leveraging a proprietary platform that conjugates short‐range radioactive isotopes with peptides and antibodies, the company aims to deliver precision radiation directly to tumor sites while minimizing exposure to healthy tissue. Its products are designed to address a range of solid tumors and hematological malignancies, offering both therapeutic and imaging applications.

The company’s pipeline includes several lead candidates in various stages of preclinical and early clinical development. Among these are alpha‐emitting therapeutics targeting prostate cancer, neuroendocrine tumors and other advanced solid tumors. In parallel, Perspective Therapeutics is advancing companion diagnostic agents to improve patient selection and monitor treatment response in real time. Research collaborations with academic medical centers and strategic partnerships with international specialists support ongoing efforts to optimize dosage, enhance tumor targeting and streamline regulatory pathways.

Headquartered in San Mateo, California, Perspective Therapeutics operates research facilities in the United States and maintains collaborative research sites in Europe and Asia. The company’s global footprint allows it to conduct multi‐center clinical trials and engage with regulators across key markets. This international approach is designed to accelerate patient access to novel radiopharmaceuticals and establish a robust data package to support future product approvals.

Founded in 2019, Perspective Therapeutics brings together a leadership team with extensive experience in radiochemistry, oncology drug development and regulatory affairs. Chief Executive Officer Dr. Cynthia Knill has over two decades of experience in nuclear medicine, while Chief Financial Officer Maria Lopez has led multiple biotech financings and public offerings. The board of directors includes industry veterans and academic researchers who guide the company’s strategic direction and foster innovation in targeted cancer therapies.

Key Stats

• Today's Range: $3.81 to $4.15
• 50-Day Range: $2.16 to $4.11
• 52-Week Range: $1.60 to $16.55
• Volume: 763,558 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $302.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.56
• Consensus Rating: Buy

Perspective Therapeutics Stock Analysis - MarketRank™

Perspective Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 647th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Perspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Perspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.20) per share.

Price to Book Value per Share Ratio

Perspective Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.53% of the float of Perspective Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Perspective Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Perspective Therapeutics has recently increased by 11.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Perspective Therapeutics does not currently pay a dividend.

Dividend Growth

Perspective Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.53% of the float of Perspective Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Perspective Therapeutics has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Perspective Therapeutics has recently increased by 11.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Perspective Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Perspective Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 14 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

MarketBeat Follows

6 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.52% of the stock of Perspective Therapeutics is held by insiders.

Percentage Held by Institutions

54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CATX Stock Analysis - Frequently Asked Questions

How have CATX shares performed this year?

Perspective Therapeutics' stock was trading at $3.19 at the start of the year. Since then, CATX stock has increased by 26.8% and is now trading at $4.0450.

How were Perspective Therapeutics' earnings last quarter?

Perspective Therapeutics, Inc. (NYSE:CATX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.21). The business earned $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative trailing twelve-month return on equity of 27.40%.

When did Perspective Therapeutics' stock split?

Shares of Perspective Therapeutics reverse split on the morning of Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Perspective Therapeutics' major shareholders?

Top institutional investors of Perspective Therapeutics include Taylor & Morgan Wealth Management LLC (0.13%) and Wealth Effects LLC (0.03%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Robert F Williamson III, Johan M Spoor, Jonathan Robert Hunt, Juan Graham and Heidi Henson.
View institutional ownership trends.

How do I buy shares of Perspective Therapeutics?

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Perspective Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/16/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:CATX
• Previous Symbol: NYSE:CATX
• CIK: 728387
• Web: www.perspectivetherapeutics.com
• Phone: 206-676-0900
• Fax: 509-267-3670
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Perspective Therapeutics: $12.56
• High Price Target: $20.00
• Low Price Target: $5.00
• Potential Upside/Downside: +223.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.18
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.51 million
• Net Margins: -4,096.66%
• Pretax Margin: -3,780.02%
• Return on Equity: -27.40%
• Return on Assets: -23.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.60
• Quick Ratio: 9.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 74,228,000
• Free Float: 65,209,000
• Market Cap: $288.00 million
• Optionable: Optionable
• Beta: 1.18